Costo anual de la atención médica de pacientes  con dermatitis atópica moderada a grave en México.  Estudio multicéntrico

Guevara-Sanginés, Esther; Pérez-Rojas, Diego Olin; Nevárez-Sida, Armando; Aceves, Martha Alicia; Barrón-Tapia, María Teresa; Abaroa-Cantú, Fernando Jorge; Ancona-Castro, Circe; García-Salazar, María del Rosario; Hernández-Rodríguez, Jimena Miguel; García-Contreras, F; Estrada-Aguilar, Lorena

doi:10.29262/ram.v67i1.700

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Literature on current cost analyses in adult AD stratifying for different patient groups is rare. In a study from Mexico, higher costs were associated with younger patients with comorbidities and with a diagnosis of depression 9 . Further studies aim predominantly at severity.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Determinants of costs and benefits in atopic dermatitis routine care in Germany

Mohr

Augustin

Zeervi

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background and objectivesThe economic burden of atopic dermatitis (AD) is of particular interest. The present study aims to analyse the association of disease-related characteristics, annual costs and treatment benefits in AD.Methods Between August 2017 and June 2019, a cross-sectional observational study in patients with AD was conducted in Germany. Cost-of-illness data were assessed from the societal perspective. Disease characteristics included severity, time since diagnosis and therapy, as well as atopic comorbidity and the implementation of prevention measures. Subgroup analyses of the total costs were conducted for these characteristics. A linear regression model was applied to analyse the impact of disease characteristics on the costs. Furthermore, associations of biologic treatment with outcome parameters were analysed.Results A total of 1291 patients from 111 centres were included in the analyses. The total costs amounted on average to € 3660 AE € 6428 per patient and year. Higher costs were shown in various patient groups, for example, in patients using biologics (€ 20 983 vs. € 2470). In a regression analysis, gender, education and the number of implemented prevention measures were identified as significant predictors of costs. Patients treated with biologics showed consistently better outcome parameters and were more often satisfied with their treatment. Conclusions Gender, education and implemented prevention measures are significant cost determinants in AD. The results confirm that treatment with biologics is the main cost driver in AD. However, incremental patient-relevant benefits of high-priced therapy are reflected by the significantly better clinical outcomes in the group treated with biologics.

show abstract

Section: Introductionmentioning

confidence: 98%

“…In a study from Mexico, higher costs were associated with younger patients with comorbidities and with a diagnosis of depression. 9 Further studies aim predominantly at severity. A study from Japan found increasing costs for higher severity grades.…”

Section: Introductionmentioning

confidence: 99%

Determinants of costs and benefits in atopic dermatitis routine care in Germany

Mohr

Augustin

Zeervi

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Interleukin-31 as a Clinical Target for Pruritus Treatment

Kabashima

Irié

2021

Front. Med.

View full text Add to dashboard Cite

In recent years, the published literature has suggested the key involvement of the cytokine interleukin-31 (IL-31) in the symptomatology of pruritus, and both IL-31 and its receptor have become potential therapeutic targets for a range of pruritic diseases. Elevated levels of IL-31 or its receptor have been reported in the tissue or serum of patients with pruritic skin diseases, such as atopic dermatitis, prurigo nodularis, and psoriasis. Pruritus places a heavy burden on patients, and can have a negative impact on daily life, sleep, and mental health. Since current anti-pruritic treatments are often ineffective, affected patients are in urgent need of new therapies. As a result, drug development targeting the IL-31 pathway is evolving rapidly. To date, only nemolizumab, a humanized monoclonal antibody targeting the IL-31 receptor, has successfully completed late-stage clinical studies. This article will highlight our current clinical understanding of the role of IL-31 in pruritic disease, and explore recent progress in drug development as well as the anticipated future advances in this field.

show abstract

Costo anual de la atención médica de pacientes con dermatitis atópica moderada a grave en México. Estudio multicéntrico

Cited by 2 publications

References 21 publications

Determinants of costs and benefits in atopic dermatitis routine care in Germany

Determinants of costs and benefits in atopic dermatitis routine care in Germany

Interleukin-31 as a Clinical Target for Pruritus Treatment

Contact Info

Product

Resources

About